bioAffinity Technologies: Poised for Record Growth in 2025
bioAffinity Technologies, Inc. (Nasdaq: BIAF), a pioneering biotechnology company dedicated to developing noninvasive diagnostic tests for early-stage cancer, is making impressive strides that indicate a prosperous future. With the ongoing success of its pilot marketing program and a surge in sales of the CyPath® Lung test, the company is on a path towards expansion and achieving record revenues by 2025.
Impressive Revenue Projections
The company’s subsidiary, Precision Pathology Laboratory Services (PPLS), is projected to generate over $9.4 million in revenue for 2024. This reflects more than a 20% increase in annualized revenue compared to 2023, especially following the acquisition of PPLS in September 2023. Remarkably, there has been a staggering 1,750% rise in sales of the CyPath® Lung test compared to the same timeframe last year.
CEO Maria Zannes on Future Prospects
Maria Zannes, President and CEO of bioAffinity Technologies, emphasized the significant potential for revenue growth driven by the seamless integration of Precision Pathology into the larger company framework. With broader acceptance and demand for CyPath® Lung, she believes that numerous milestones have already been achieved in 2024, such as securing reimbursement for the test, broadening the sales team, and streamlining operations.
Strategic Market Expansion
Looking ahead, the revenue from CyPath® Lung is anticipated to burgeon in 2025 as the company aims to penetrate strategic national markets and gain entry into the U.S. Federal Supply Schedule. This procurement system plays a crucial role in providing advanced healthcare solutions to organizations such as the Veterans Health Administration and the Military Health System.
The Importance of CyPath® Lung
CyPath® Lung fills a critical gap in the realm of lung cancer detection, specifically targeting patients at high risk. It serves as a noninvasive tool that can be used independently or in conjunction with other diagnostic procedures, establishing itself as a vital component of next-generation lung cancer care.
Innovative Technology Behind CyPath® Lung
Utilizing advanced flow cytometry alongside artificial intelligence (AI), CyPath® Lung is capable of identifying cell populations in patient sputum indicative of malignancy. The cutting-edge automated data analysis further aids in determining the presence of cancer or confirming that a patient is cancer-free. By integrating a fluorescent porphyrin compound, meso-tetra (4-carboxyphenyl) porphyrin (TCPP), the test enhances the sensitivity of cancer detection effectively. Clinical studies have shown that CyPath® Lung boasts 92% sensitivity and 88% accuracy in discerning lung cancer in individuals with small nodules.
About bioAffinity Technologies, Inc.
bioAffinity Technologies stands at the forefront of the need for effective noninvasive diagnostic methods for early-stage cancer and diseases affecting the lungs. The company's flagship product, CyPath® Lung, is designed to achieve high standards in sensitivity and accuracy for early lung cancer detection. As a Laboratory Developed Test (LDT), it is marketed by Precision Pathology Laboratory Services, showcasing the company’s commitment to innovation in healthcare.
Frequently Asked Questions
What is bioAffinity Technologies known for?
bioAffinity Technologies, Inc. focuses on developing noninvasive diagnostic tests for early-stage cancer, particularly in lung cancer detection.
What is the CyPath® Lung test?
CyPath® Lung is a noninvasive test using advanced technology to detect early-stage lung cancer in high-risk patients.
What revenue growth is expected for bioAffinity Technologies?
The company anticipates a revenue growth exceeding 20% in 2024, with projections of reaching approximately $9.4 million.
How does CyPath® Lung benefit patients?
CyPath® Lung helps improve early detection of lung cancer, potentially leading to better treatment outcomes and increased survival rates.
Where can I find more information about bioAffinity Technologies?
For more details, visit the official bioAffinity Technologies website or follow their updates via social media platforms.
